Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response.
Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Wit S, Florence E, Fransen K, Ribas SG, Marissens D, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM. Derdelinckx I, et al. Among authors: de wit s. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1664-6. doi: 10.1097/00126334-200412150-00022. J Acquir Immune Defic Syndr. 2004. PMID: 15577426 Free article. Clinical Trial. No abstract available.
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ. Vandekerckhove L, et al. Among authors: de wit s. J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31. J Antimicrob Chemother. 2011. PMID: 21196489 Free PMC article.
Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.
Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A; EuroSIDA in EuroCoord (European Coordinating Committee for the Integration of Ongoing Coordination Actions Related to Clinical and Epidemiological HIV Research). Grint D, et al. HIV Med. 2013 Jul;14(6):370-8. doi: 10.1111/hiv.12033. Epub 2013 Mar 27. HIV Med. 2013. PMID: 23534815 Free article.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.
De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Günthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schülter E, Torti C, van Sighem A, Zangerle R, Descamps D; CHAIN and COHERE in EuroCoord. De Luca A, et al. Among authors: de wit s. J Antimicrob Chemother. 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465. Epub 2016 Jan 28. J Antimicrob Chemother. 2016. PMID: 26825119 Free PMC article.
Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.
Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, Fidler S, Lehmann C, Zangerle R, Wittkop L, Reiss P, Hamouda O, Estrada Perez V, Leal M, Mocroft A, Garcia De Olalla P, Ammassari A, D'Arminio Monforte A, Mussini C, Segura F, Castagna A, Cavassini M, Grabar S, Morlat P, De Wit S, Lambotte O, Meyer L; HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD. Chereau F, et al. Among authors: de wit s. PLoS One. 2017 Apr 5;12(4):e0173893. doi: 10.1371/journal.pone.0173893. eCollection 2017. PLoS One. 2017. PMID: 28380038 Free PMC article.
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*. Gatell JM, et al. Among authors: de wit s. AIDS. 2017 Nov 28;31(18):2503-2514. doi: 10.1097/QAD.0000000000001675. AIDS. 2017. PMID: 29112070 Free PMC article. Clinical Trial.
Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.
De Wit S, Florence E, Vandekerckhove L, Vandercam B, Goffard JC, Van Wijngaerden E, Moutschen M, Demeester R, Thilakarathne P, Piryns H; BREACH* Consortium. De Wit S, et al. Acta Clin Belg. 2018 Oct;73(5):341-347. doi: 10.1080/17843286.2018.1458428. Epub 2018 Apr 6. Acta Clin Belg. 2018. PMID: 29623779 Free article.
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group. Gatell JM, et al. Among authors: de wit s. Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505. Clin Infect Dis. 2019. PMID: 29912307 Clinical Trial.
584 results